HK1247112A1 - 用夾竹桃屬物種或黃花夾竹桃屬物種的提取物治療神經病症的方法 - Google Patents

用夾竹桃屬物種或黃花夾竹桃屬物種的提取物治療神經病症的方法

Info

Publication number
HK1247112A1
HK1247112A1 HK18106778.5A HK18106778A HK1247112A1 HK 1247112 A1 HK1247112 A1 HK 1247112A1 HK 18106778 A HK18106778 A HK 18106778A HK 1247112 A1 HK1247112 A1 HK 1247112A1
Authority
HK
Hong Kong
Prior art keywords
species
extract
neurological conditions
treating neurological
thevetia
Prior art date
Application number
HK18106778.5A
Other languages
English (en)
Inventor
O‧C‧阿丁頓
R‧A‧紐曼
Original Assignee
菲尼克斯生物技術公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2011/020672 external-priority patent/WO2011085307A1/en
Application filed by 菲尼克斯生物技術公司 filed Critical 菲尼克斯生物技術公司
Publication of HK1247112A1 publication Critical patent/HK1247112A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
HK18106778.5A 2010-11-22 2018-05-24 用夾竹桃屬物種或黃花夾竹桃屬物種的提取物治療神經病症的方法 HK1247112A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41594510P 2010-11-22 2010-11-22
PCT/US2011/020672 WO2011085307A1 (en) 2010-01-11 2011-01-10 Method of treating neurological conditions with cardiac glycosides
US12/987,693 US8481086B2 (en) 2010-01-11 2011-01-10 Method of treating neurological conditions with cardiac glycoside

Publications (1)

Publication Number Publication Date
HK1247112A1 true HK1247112A1 (zh) 2018-09-21

Family

ID=46146352

Family Applications (2)

Application Number Title Priority Date Filing Date
HK14103098.9A HK1189764A1 (zh) 2010-11-22 2014-04-01 用於治療神經學病症的夾竹桃或黃花夾竹桃提取物
HK18106778.5A HK1247112A1 (zh) 2010-11-22 2018-05-24 用夾竹桃屬物種或黃花夾竹桃屬物種的提取物治療神經病症的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK14103098.9A HK1189764A1 (zh) 2010-11-22 2014-04-01 用於治療神經學病症的夾竹桃或黃花夾竹桃提取物

Country Status (12)

Country Link
EP (1) EP2642859B1 (zh)
JP (3) JP6453538B2 (zh)
KR (2) KR101742852B1 (zh)
CN (2) CN107412775B (zh)
AU (1) AU2011332248B2 (zh)
BR (1) BR112013012504A2 (zh)
CA (1) CA2818601C (zh)
ES (1) ES2546518T3 (zh)
HK (2) HK1189764A1 (zh)
MX (1) MX345675B (zh)
RU (1) RU2606594C2 (zh)
WO (1) WO2012071152A2 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140066488A1 (en) * 2012-08-30 2014-03-06 Purdue Research Foundation Inhibitors of Memapsin 2 Cleavage for the Treatment of Alzheimer's Disease
EP2996684A4 (en) * 2013-03-15 2016-11-30 Univ Iowa Res Found THERAPEUTIC PROCEDURES
CN104914193B (zh) * 2015-06-29 2016-08-10 公安部物证鉴定中心 生物样品中夹竹桃苷和夹竹桃苷乙的液相色谱-串联质谱检验方法
CN105878316A (zh) * 2016-04-11 2016-08-24 天津中医药大学 黄花夹竹桃叶中总强心苷的提取方法及含量测定方法
EP3681477A4 (en) * 2017-09-14 2021-06-09 Phoenix Biotechnology, Inc. IMPROVED METHOD AND COMPOSITION FOR THE TREATMENT OF CONDITIONS, DISEASES OR DISORDERS SENSITIVE TO TRITERPENES
WO2020100917A1 (ja) 2018-11-13 2020-05-22 グリーン・テック株式会社 神経変性疾患の予防剤及び／又は治療剤
CN110487934A (zh) * 2019-08-30 2019-11-22 浙江工业大学 齐墩果酸和熊果酸的分析方法
CN111494390B (zh) * 2020-05-18 2022-08-19 南通大学 白桦醇衍生物在制备修复神经损伤药物中的新用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236132A (en) 1992-01-03 1993-08-17 Vortec, Inc. Gradient-force comminuter/dehydrator apparatus and method
US5598979A (en) 1995-04-20 1997-02-04 Vortec, Inc. Closed loop gradient force comminuting and dehydrating system
JP2000247993A (ja) * 1999-03-01 2000-09-12 Toray Ind Inc トリテルペノイド系化合物を含んでなるσレセプター作用薬
CN1129613C (zh) * 1999-12-24 2003-12-03 中国科学院上海药物研究所 夹竹桃花多糖及其制备方法和应用
US6517015B2 (en) 2000-03-21 2003-02-11 Frank F. Rowley, Jr. Two-stage comminuting and dehydrating system and method
JP2002078468A (ja) * 2000-09-06 2002-03-19 Takenori Kato 耐熱性金属イオンゲル入り飲料
US6715705B2 (en) 2001-03-16 2004-04-06 Frank F. Rowley, Jr. Two-stage comminuting and dehydrating system and method
US20040082521A1 (en) 2002-03-29 2004-04-29 Azaya Therapeutics Inc. Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases
US20060234955A1 (en) * 2002-05-28 2006-10-19 Bette Pollard Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders
JP2006508126A (ja) 2002-11-06 2006-03-09 アザヤ セラピューティクス インコーポレイティッド 薬学的製剤のタンパク質安定化されたリポソーム製剤
US20050026849A1 (en) 2003-03-28 2005-02-03 Singh Chandra U. Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases
US20110229563A1 (en) * 2003-12-19 2011-09-22 Frederick William Cain Use of compositions comprising oleanic acid and ursolic acid for the preparation of a medicament for the treatment of hypersensitivity and hyperreactivity
US7529217B2 (en) 2004-03-27 2009-05-05 Dust Networks, Inc. Low-power autonomous node for mesh communication network
US20060135443A1 (en) * 2004-10-18 2006-06-22 Bionaut Pharmaceuticals, Inc. Use of Na*/K*-ATPase inhibitors and antagonists thereof
US7402325B2 (en) * 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
RU2571687C2 (ru) * 2007-11-13 2015-12-20 Феникс Байотекнолоджи Инк. Набор для определения вероятности терапевтического ответа на противораковую химиотерапию сердечным гликозидом
EP2254886B1 (en) * 2008-03-28 2016-05-25 Nerviano Medical Sciences S.r.l. 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
ES2326065B1 (es) * 2008-03-28 2010-07-08 Consejo Superior De Investigaciones Cientificas (Csic) Utilizacion de un triterpeno pentaciclico para la preparacion de una composicion farmaceutica destinada al tratamiento de la esclerosis multiple.
KR101774181B1 (ko) * 2010-01-11 2017-09-01 피닉스 바이오테크놀러지 인코포레이티드. 강심 배당체로 신경계 질환을 치료하는 방법

Also Published As

Publication number Publication date
AU2011332248B2 (en) 2015-08-13
KR20140005903A (ko) 2014-01-15
BR112013012504A2 (pt) 2017-06-27
JP2013542988A (ja) 2013-11-28
EP2642859A2 (en) 2013-10-02
CA2818601C (en) 2022-03-29
JP2017114888A (ja) 2017-06-29
WO2012071152A4 (en) 2012-08-16
JP2016145223A (ja) 2016-08-12
KR101742852B1 (ko) 2017-06-15
RU2606594C2 (ru) 2017-01-10
CN107412775B (zh) 2021-01-05
CN107412775A (zh) 2017-12-01
HK1189764A1 (zh) 2014-06-20
WO2012071152A2 (en) 2012-05-31
CN103429251B (zh) 2017-09-15
JP6453791B2 (ja) 2019-01-16
ES2546518T3 (es) 2015-09-24
WO2012071152A3 (en) 2012-06-21
AU2011332248A1 (en) 2013-06-13
KR20170049623A (ko) 2017-05-10
MX345675B (es) 2017-02-10
JP6453538B2 (ja) 2019-01-16
EP2642859B1 (en) 2015-08-12
MX2013005739A (es) 2014-02-03
RU2013128609A (ru) 2014-12-27
EP2642859A4 (en) 2014-05-28
CN103429251A (zh) 2013-12-04
CA2818601A1 (en) 2012-05-31

Similar Documents

Publication Publication Date Title
HK1247112A1 (zh) 用夾竹桃屬物種或黃花夾竹桃屬物種的提取物治療神經病症的方法
IL276362A (en) Cancer treatment methods
AU2016202421A1 (en) Method of treating neurological conditions with cardiac glycosides
EP2523563A4 (en) METHOD OF TREATING NEUROLOGICAL DISEASES USING CARDIAC GLYCOSIDES
IL223189A0 (en) Methods of treatment of pancreatic cancer
EP2643001A4 (en) METHOD OF TREATING CANCER
EP2582374A4 (en) METHOD FOR TREATING NERVOUS ELEMENTS
ZA201205004B (en) Methods for treating pancreatic cancer
HK1201439A1 (zh) 治療或降低 的方法
HK1189272A1 (zh) 治療癌症的方法
GB201018147D0 (en) Method of treatment
IL232493A0 (en) A method for quantifying cancer treatment
GB201003920D0 (en) Method of treatment
GB201013975D0 (en) Method of treating desease
EP2713883A4 (en) METHODS FOR PREVENTING AND TREATING NEUROLOGICAL CONDITIONS RELATED TO MOTOR FUNCTION
EP2640390A4 (en) METHODS OF TREATING CANCER
IL229705A0 (en) Methods for the treatment or prevention of neurological diseases
IL218230A0 (en) Method of treating cancer
EP2632459A4 (en) METHOD OF TREATING NEUROENDOCRINE TUMORS
EP2560648A4 (en) METHOD OF TREATING PANCREATIC CANCER
EP2509599A4 (en) METHOD FOR THE TREATMENT OF PANCREATIC CANCER
EP2585103A4 (en) METHOD OF TREATMENT
GB201018149D0 (en) Method of treatment
GB201020015D0 (en) Method of treatment
EP2566563A4 (en) IMPROVED METHOD FOR TREATING PURGEON GASES